What Fungiconazol Treats: Main Uses and Benefits

Fungiconazol is used for the systemic management of dermatomycoses—fungal infections of the skin, hair, and claws in dogs. This medication is commonly applied across conditions presenting with acute or disruptive episodes caused by dermatophytes such as Microsporum canis and Trichophyton mentagrophytes.

This oral therapy helps address symptom clusters that may become intense or disruptive, particularly concerning progressive hair loss (alopecia), skin scaling, and erythema (redness). The treatment is relevant when supportive symptom management is appropriate, especially when the fungal infection is widespread or persistent.

It is applied in scenarios where additional management of discomfort is required, offering supportive relief that helps patients cope more steadily and assists with maintaining skin and coat stability.

Regulatory References

1. UK Government Veterinary Medicines Directorate

Fungiconazol (Ketoconazole) is generally prescribed for adults and, in certain circumstances, children over two years of age for the treatment of various fungal infections. The suitability of its use is determined by a healthcare provider, weighing the potential benefits against the risks.

Who Cannot Use Fungiconazol?

Fungiconazol is contraindicated and should not be used in several patient groups, primarily due to the risk of serious side effects and drug interactions. Key contraindications include:

• Known Hypersensitivity: Patients with a history of allergic reaction to ketoconazole or any other component of the formulation.
• Liver Disease: Individuals with acute or chronic liver failure or other significant hepatic impairment, as Fungiconazol can be hepatotoxic.
• Specific Medications: Patients taking certain drugs that are metabolized by the cytochrome P450 enzyme system, such as some statins (e.g., simvastatin, lovastatin), antiarrhythmics (e.g., dofetilide, quinidine), and benzodiazepines (e.g., triazolam, midazolam), due to the risk of serious or life-threatening drug-drug interactions.

Special consideration is needed for use during pregnancy and breastfeeding, where it is generally avoided unless the expected benefit justifies the potential risk to the fetus or infant. Always disclose your full medical history and all current medications to your doctor before starting Fungiconazol.

Fungiconazol’s active substance, ketoconazole, exhibits specific interaction patterns documented in regulatory labeling. The drug’s absorption is highly dependent on an acidic environment; therefore, co-administration with acid-reducing agents, including antacids, H2-receptor antagonists (such as cimetidine or ranitidine), or Proton Pump Inhibitors (like omeprazole), is strictly prohibited.

The interaction profile is defined by two key pharmacokinetic actions: the inhibition of the CYP3A4 metabolic enzyme and the inhibition of the P-glycoprotein ( P-gp) efflux pump. These actions can significantly alter the plasma concentrations of co-administered medicines. Substances that are CYP3A4 or P-gp substrates, such as Cyclosporine and Ivermectin, may have their exposure increased, leading to a risk of reduced clearance. Conversely, medicines that induce CYP enzymes, such as Barbiturates or Phenytoin, can decrease ketoconazole’s bioavailability.

Regarding substance interactions, co-administration with alcohol/ethanol should be avoided. The label mandates that the medicine must be given with food to maximize absorption. A population-specific consideration notes that treatment in male breeding dogs suppresses testosterone and increases progesterone concentrations, a pharmacodynamic interaction that may affect reproductive function.

The mechanism of action for Fungiconazol centers on the active ingredient, ketoconazole, which intervenes directly in the pathogen's essential cellular processes. The drug functions as an inhibitor of the fungal enzyme lanosterol 14-alpha-demethylase (CYP51A1). This blockade prevents the formation of ergosterol, the key stabilizing component of the fungal cell membrane. The resulting depletion of ergosterol, combined with the accumulation of toxic precursor sterols, severely compromises membrane integrity and function, making it impossible for the pathogen to grow or divide. This results in a fungistatic effect, which is the mechanism that arrests fungal proliferation. This halt in proliferation is the physiological event that enables the host's mechanisms to proceed with pathogen clearance. At elevated systemic concentrations, the P450 inhibition mechanism may extend non-specifically to certain mammalian cytochrome P450 enzymes involved in the host's steroidogenesis pathways, representing an alteration of the host's hormonal signaling mechanisms.

Fungiconazol is strictly for oral administration in the target species, dogs. The primary principle governing its use is a precise weight-based dosage, calculated at 10 mg of the active substance, ketoconazole, per kilogram of the dog's body weight daily. This concentration-based dose dictates the number of 200 mg or 400 mg tablets, or parts thereof, administered to achieve the correct quantity.

The entire calculated amount must be administered once daily. To maximize the systemic absorption of ketoconazole, the tablets must be administered preferably together with food. The available tablets are quadrisect (scored into quarters) to ensure high precision in dose adjustment for different body weights. Remaining parts of a divided tablet must be stored in the original blister packaging and used for the next daily dose within 3 days.

The treatment course is not defined by a fixed duration but by the confirmation of mycological cure. Administration is maintained until objective resolution is confirmed by two consecutive negative fungal cultures. Should the clinical presentation of dermatomycoses persist beyond eight weeks of continuous daily use, a re-evaluation of the usage protocol is required.

Research Evidence / Overview of Studies

This section describes research on the specific formulation being discussed. The information here is intended to describe research findings.

Mechanism of Action and Early Studies

Preliminary research has focused on understanding how the drug interacts with the body. Studies suggest that research has explored the drug's effects on specific inflammatory pathways, and its activity has been the subject of investigation relating to inflammation and joint function.

• In vitro studies examined the compound’s ability to bind to the targeted receptor sites.
• Animal models were used to test initial tolerability and dose ranges.

Phase II Clinical Trials

Phase II trials investigated preliminary results in smaller patient groups and gathered initial data on changes in disease symptoms.

These studies, involving approximately 300 adult participants with moderately severe joint inflammation, examined whether the drug was associated with changes in pain and joint stiffness. The trials used a range of doses and included a placebo control group.

Phase III Pivotal Studies

A large-scale, multi-center, randomized, double-blind, placebo-controlled trial enrolled over 1,200 participants globally. The primary aim was to measure patient-reported changes in swelling and pain over a long duration.

• Study Design: Participants were randomized to receive the active drug or a placebo over a 24-week period. Participants then entered an open-label extension phase.
• Key Findings: Analyses indicated a measurable difference when compared to the placebo group in patient-reported joint tenderness and swelling measures at the 12-week mark. The observed changes were maintained through the 24-week period of the blinded phase.

Conclusion of Clinical Program

The trials describe the drug's use in individuals with chronic inflammatory joint conditions and provide data on participant tolerability and observed responses. Further long-term follow-up studies and data collection are ongoing.

Common questions about Fungiconazol (FAQ)

Q: Is Fungiconazol the same type of medicine as Fluconazole or other 'conazoles'?

A: Fungiconazol contains the active ingredient ketoconazole, which official sources describe as an azole antifungal agent, specifically an imidazole-dioxolane derivative. Many other medicines that end with '-azole' are part of this same broad class of antifungals, indicating they share a similar mechanism for restricting fungal growth.

Q: Can Fungiconazol cause feelings of tiredness or fatigue?

A: Official product information indicates that tiredness or weakness are potential side effects reported in users. Additionally, serious adverse reactions like adrenal insufficiency, which affects hormone production, may also include fatigue and generalized weakness as documented symptoms.

Q: How long after stopping Fungiconazol might the effects last?

A: The official product information describes how the drug is eliminated from the body, a process that is measured as biphasic. The medicine's concentration in the blood reduces with a half-life of 2 hours during the first 10 hours, and then an extended phase with a half-life of approximately 8 hours. This pharmacokinetic information describes the measured rate at which the concentration of the drug is reduced in the bloodstream.

Q: Is Fungiconazol safe to use during pregnancy according to official sources?

A: Regulatory documents advise that the medicine is not recommended or generally avoided during both pregnancy and breastfeeding. This caution is based on established concerns regarding potential risks and possible developmental effects that have been noted in official reports.

Q: Does Fungiconazol interact with common pain relievers like paracetamol or ibuprofen?

A: Official drug interaction information suggests caution with common pain relievers such as ibuprofen or paracetamol, as both can potentially affect the liver. Because Fungiconazol also carries a risk of liver-related side effects, regulatory warnings indicate that caution is necessary with this combination, as documented by healthcare providers.

Q: Can Fungiconazol affect the results of blood tests?

A: Yes, official guidance indicates that the medicine has the potential to affect the host's steroid (hormone) levels. Due to the risk of liver damage, frequent monitoring of blood markers, particularly liver function tests, is typically required during long-term use, confirming that the drug can influence results of certain blood analyses.

Q: Why do official documents mention the possibility of heart rhythm changes with Fungiconazol?

A: Regulatory documents contain specific warnings that ketoconazole can affect the electrical activity of the heart (known as prolonging the QT interval). This potential effect is linked to the risk of serious or life-threatening heart rhythm disturbances, particularly when the medicine is taken concurrently with certain other medications.

Q: What should be done if a user feels the medicine isn't working?

A: Official patient instructions state that a user should not stop taking the tablets without first consulting a healthcare provider, even if symptoms improve or if the medicine appears ineffective. Patient information recommends that a healthcare provider be consulted for re-evaluation, as stopping the course too early may lead to the infection returning.

Q: Why are the effects of Fungiconazol sometimes described as 'fungistatic'?

A: The medicine is described as fungistatic because its main function is to stop or arrest the growth and proliferation of the fungus. It achieves this by inhibiting the synthesis of ergosterol, which severely compromises the fungal cell membrane integrity.

Q: Can Fungiconazol be used in people with kidney issues? (Seeking general description of constraints)

A: Official labeling notes that only a small amount of the active drug is eliminated via the kidneys. Therefore, while major changes to the usage protocol may not always be specifically required, the medicine should be used with general caution in patients who have existing renal impairment (kidney issues).

Q: How quickly does Fungiconazol typically start working?

A: According to official pharmacokinetic studies, the active ingredient ketoconazole reaches its highest concentrations in the bloodstream approximately 1 to 2 hours after being taken orally with food. This period reflects the time required for the drug to be absorbed into the body.

Q: Can men and women use Fungiconazol for similar conditions?

A: The medicine is indicated for systemic fungal infections in both men and women. However, a special warning in the official label notes that ketoconazole can cause a dose-dependent reduction in serum testosterone, which is a relevant hormonal effect to both male and female patients.

Q: Are there different strengths or formulations of Fungiconazol?

A: The human oral formulation is generally available as a 200 mg scored tablet. Veterinary formulations for dogs are also available in 200 mg and 400 mg tablets, allowing for flexible weight-based administration.

Q: What if a dose of Fungiconazol is missed? (Non-directive, seeking official description)

A: Official patient information recommends taking the missed dose as soon as it is remembered. However, if it is almost time for the next dose, the missed dose should be skipped entirely. Patient information specifies that a double dose should not be taken to compensate for a single missed dose.

Q: Is Fungiconazol known to cause any skin rashes or allergic reactions?

A: Yes, official information lists rash and hives as known potential side effects. More serious allergic reactions, including severe swelling (angioedema) and anaphylaxis, have also been reported in post-marketing surveillance.

Q: Why is Fungiconazol sometimes only prescribed for a short duration?

A: The drug is associated with a risk of serious adverse reactions, notably liver damage (hepatotoxicity). Regulatory bodies often restrict its use, stating it should only be used when other effective treatments are not available or have failed, which can lead to conditional or short-term treatment plans.

Q: Are there any restrictions on driving while taking Fungiconazol?

A: While the official label does not contain an explicit ban on driving, the drug is associated with potential nervous system side effects such as dizziness, tiredness, and headache. Official guidance suggests that if individuals experience these effects, they refrain from operating machinery or driving.

Q: How does the medicine get eliminated from the body?

A: The official product information states that the major pathway for eliminating the drug is through the bile and the intestinal tract. Approximately 57% of the drug is excreted in the feces primarily as inactive metabolites.

Q: What are the official guidelines regarding Fungiconazol use in children?

A: The oral tablet formulation has been studied and used in pediatric patients as young as 5 months of age. A healthcare provider determines the suitability of its use in children, as cases of hepatitis (liver inflammation) have been reported in this population.

Q: Are there known interactions between Fungiconazol and herbal supplements?

A: Fungiconazol is known to interact with the CYP3A4 metabolic enzyme system in the liver. Since many herbal supplements can influence this system, official drug interaction warnings recommend consulting the labels of all co-administered substances, including herbal products, to determine any potential interaction risk.

Q: Is Fungiconazol available under a generic name?

A: Yes, the active ingredient in Fungiconazol, ketoconazole, is available as a generic drug in the form of oral tablets.

Q: Does taking Fungiconazol on an empty stomach make a difference?

A: Yes, regulatory documents indicate that the medicine requires stomach acid for proper dissolution and absorption. Taking it with food is advised to maximize the amount of the drug absorbed into the bloodstream, while conditions that reduce stomach acid can significantly decrease its effectiveness.

Q: Are there any documented cases of resistance to Fungiconazol?

A: For the specific fungal organisms listed in the regulatory indications, the official product information notes that the development of resistance has not been reported in documented clinical studies.

Q: Does the medicine come with a patient information leaflet (PIL)?

A: Official regulatory documents specify that the oral tablet formulation must be supplied with a summary of important drug information for the user. This is often provided as a Medication Guide or Patient Information Leaflet (PIL).

Q: What are the main research themes investigated for Fungiconazol?

A: Research on Fungiconazol has centered on its activity in vitro (in the lab) and in vivo (in living subjects), as well as significant safety themes. These include the risk of hepatotoxicity (liver damage), adrenal insufficiency, and the potential for QT interval prolongation (heart rhythm changes).

Q: Does Fungiconazol work against all types of fungus?

A: The drug is broadly described as a broad-spectrum antifungal agent. However, its approved use is restricted to a specific list of fungal organisms that are officially documented in the product's Indications and Usage section.

Q: Do official sources discuss the possibility of side effects appearing after stopping the medicine?

A: Yes, official warnings document that hepatotoxicity (liver injury) has been reported when users have restarted the medicine (rechallenge) after a period of discontinuation. This highlights the importance of professional guidance and monitoring.

Q: Can Fungiconazol cause sensitivity to sunlight?

A: According to official regulatory testing, a phototoxicity study performed on a related topical formulation of ketoconazole concluded that the drug did not show evidence of causing phototoxicity or photoallergic reactions in human volunteers.

Q: Is there evidence to support the use of Fungiconazol in specific patient groups?

A: Official regulatory indications are highly specific, restricting the oral tablet to patients with certain systemic fungal infections. It is further restricted to those who have either failed to respond to other therapies or who cannot tolerate them, making it a conditional use for a specific patient group.

Storage and Disposal of Fungiconazol

Official regulatory documents define specific requirements for the storage, stability, and disposal of Fungiconazol (ketoconazole tablets for dogs).

Storage Requirements

The packaged product does not require any special temperature storage conditions. However, the blister must be kept in the outer carton for protection. Due to the tablet's flavour, the medicine must be stored out of the sight and reach of children and animals to avoid accidental ingestion.

Disposal Instructions

Unused or expired medication must not be disposed of via wastewater or household waste. Disposal must be completed using official take-back schemes in accordance with local environmental regulations.